Abstract
Discusses the extent to which American, European and Japanese pharmaceutical multinational enterprises (MNE) with subsidiaries in the Republic of Ireland have localised specific forms of R&D and contributed to technology transfer. Reports on a survey in which chief executive officers of Irish‐based MNE subsidiaries responded to mailed questionnaires. The reasons for corporate management to choose such operational strategic thrusts at business level have been highlighted with a view to focus on the degree to which Ireland is developing its pharmaceutical industrial base, as a result of attracting export‐led global pharmaceutical multinationals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
